Immuron Ltd ADR


Download Data

Immuron Ltd ADR Market Capitalization on May 17, 2024: USD 13.97 M

Immuron Ltd ADR Market Capitalization is USD 13.97 M on May 17, 2024, a 2.41% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Immuron Ltd ADR 52-week high Market Capitalization is USD 25.91 M on March 07, 2024, which is 85.46% above the current Market Capitalization.
  • Immuron Ltd ADR 52-week low Market Capitalization is USD 9.06 M on November 09, 2023, which is -35.15% below the current Market Capitalization.
  • Immuron Ltd ADR average Market Capitalization for the last 52 weeks is USD 12.43 M.

Immuron Ltd ADR

CEO Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA
IPO Date June 9, 2017
Location Australia
Headquarters 62 Lygon Street, Carlton, VIC, Australia, 3053
Employees 6
Sector Healthcare
Industry Biotechnology

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Similar companies


Immix Biopharma Inc

USD 2.47


StockViz Staff

May 20, 2024

Any question? Send us an email